Recombinant Human Endostatin in Combination With mFOLFOX6 in Patients With Metastatic Colorectal Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To investigate safety and tolerance of dose-escalation of infusional recombinant human
endostatin in combination with mFOLFOX6 as initial therapy for patients with metastatic
colorectal cancer.